{"data":[{"accessionNo":"0002012383-26-003716","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001447028","issuerName":"Arbutus Biopharma Corp","ticker":"ABUS","cusip":"03879J100","securityClass":"Common Stock","eventDate":"2026-09-30","reportingPerson":"BlackRock, Inc.","reportingCik":null,"personType":"HC","sharesOwned":14331732,"percentOfClass":7.2,"filedAt":"2026-10-27","canonicalUrl":"https://xoomar.com/markets/stocks/abus"},{"accessionNo":"0000895421-26-000284","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001447028","issuerName":"Arbutus Biopharma Corp","ticker":"ABUS","cusip":"03879J100","securityClass":"Common Shares","eventDate":"2026-09-30","reportingPerson":"Morgan Stanley","reportingCik":null,"personType":"HC,CO","sharesOwned":18682708,"percentOfClass":12.2,"filedAt":"2026-10-07","canonicalUrl":"https://xoomar.com/markets/stocks/abus"},{"accessionNo":"0000895421-26-000284","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001447028","issuerName":"Arbutus Biopharma Corp","ticker":"ABUS","cusip":"03879J100","securityClass":"Common Shares","eventDate":"2026-09-30","reportingPerson":"Morgan Stanley Investment Management Inc.","reportingCik":null,"personType":"IA,CO","sharesOwned":17376366,"percentOfClass":11.3,"filedAt":"2026-10-07","canonicalUrl":"https://xoomar.com/markets/stocks/abus"},{"accessionNo":"0001140361-26-038693","formType":"SCHEDULE 13D/A","amendmentNo":14,"issuerCik":"0001447028","issuerName":"Arbutus Biopharma Corp","ticker":"ABUS","cusip":"03879J100","securityClass":"Common Shares, without par value","eventDate":"2026-10-01","reportingPerson":"Roivant Sciences Ltd.","reportingCik":"0001635088","personType":"CO","sharesOwned":29880079,"percentOfClass":19.5,"filedAt":"2026-10-05","canonicalUrl":"https://xoomar.com/markets/stocks/abus"},{"accessionNo":"0000921895-26-002494","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001447028","issuerName":"Arbutus Biopharma Corp","ticker":"ABUS","cusip":"03879J100","securityClass":"Common Shares, without par value","eventDate":"2026-09-04","reportingPerson":"David Salanic","reportingCik":null,"personType":"HC,IN","sharesOwned":15794261,"percentOfClass":8,"filedAt":"2026-09-04","canonicalUrl":"https://xoomar.com/markets/stocks/abus"},{"accessionNo":"0000921895-26-002494","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001447028","issuerName":"Arbutus Biopharma Corp","ticker":"ABUS","cusip":"03879J100","securityClass":"Common Shares, without par value","eventDate":"2026-09-04","reportingPerson":"Joseph Kaplan","reportingCik":null,"personType":"HC,IN","sharesOwned":15794261,"percentOfClass":8,"filedAt":"2026-09-04","canonicalUrl":"https://xoomar.com/markets/stocks/abus"},{"accessionNo":"0000921895-26-002494","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001447028","issuerName":"Arbutus Biopharma Corp","ticker":"ABUS","cusip":"03879J100","securityClass":"Common Shares, without par value","eventDate":"2026-09-04","reportingPerson":"Whitefort Capital Management GP, LLC","reportingCik":null,"personType":"OO","sharesOwned":15794261,"percentOfClass":8,"filedAt":"2026-09-04","canonicalUrl":"https://xoomar.com/markets/stocks/abus"},{"accessionNo":"0000921895-26-002494","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001447028","issuerName":"Arbutus Biopharma Corp","ticker":"ABUS","cusip":"03879J100","securityClass":"Common Shares, without par value","eventDate":"2026-09-04","reportingPerson":"Whitefort Capital Master Fund, LP","reportingCik":null,"personType":"PN","sharesOwned":15794261,"percentOfClass":8,"filedAt":"2026-09-04","canonicalUrl":"https://xoomar.com/markets/stocks/abus"},{"accessionNo":"0000921895-26-002494","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001447028","issuerName":"Arbutus Biopharma Corp","ticker":"ABUS","cusip":"03879J100","securityClass":"Common Shares, without par value","eventDate":"2026-09-04","reportingPerson":"Whitefort Capital GP, LLC","reportingCik":null,"personType":"OO","sharesOwned":15794261,"percentOfClass":8,"filedAt":"2026-09-04","canonicalUrl":"https://xoomar.com/markets/stocks/abus"},{"accessionNo":"0000921895-26-002494","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001447028","issuerName":"Arbutus Biopharma Corp","ticker":"ABUS","cusip":"03879J100","securityClass":"Common Shares, without par value","eventDate":"2026-09-04","reportingPerson":"Whitefort Capital Management, LP","reportingCik":null,"personType":"IA,PN","sharesOwned":15794261,"percentOfClass":8,"filedAt":"2026-09-04","canonicalUrl":"https://xoomar.com/markets/stocks/abus"},{"accessionNo":"0000895421-26-000222","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001447028","issuerName":"Arbutus Biopharma Corp","ticker":"ABUS","cusip":"03879J100","securityClass":"Common Shares","eventDate":"2026-06-30","reportingPerson":"Morgan Stanley","reportingCik":null,"personType":"HC,CO","sharesOwned":17387398,"percentOfClass":8.8,"filedAt":"2026-08-12","canonicalUrl":"https://xoomar.com/markets/stocks/abus"},{"accessionNo":"0000895421-26-000222","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001447028","issuerName":"Arbutus Biopharma Corp","ticker":"ABUS","cusip":"03879J100","securityClass":"Common Shares","eventDate":"2026-06-30","reportingPerson":"Morgan Stanley Investment Management Inc.","reportingCik":null,"personType":"IA,CO","sharesOwned":17122142,"percentOfClass":8.7,"filedAt":"2026-08-12","canonicalUrl":"https://xoomar.com/markets/stocks/abus"},{"accessionNo":"0001011438-26-000347","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001447028","issuerName":"Arbutus Biopharma Corporation","ticker":"ABUS","cusip":"03879J100","securityClass":"Common Shares, without par value","eventDate":"2026-03-31","reportingPerson":"Sina Toussi","reportingCik":null,"personType":"IN,HC","sharesOwned":18557543,"percentOfClass":9.4,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/abus"},{"accessionNo":"0001011438-26-000347","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001447028","issuerName":"Arbutus Biopharma Corporation","ticker":"ABUS","cusip":"03879J100","securityClass":"Common Shares, without par value","eventDate":"2026-03-31","reportingPerson":"Two Seas Capital GP LLC","reportingCik":null,"personType":"OO,HC","sharesOwned":18557543,"percentOfClass":9.4,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/abus"},{"accessionNo":"0001011438-26-000347","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001447028","issuerName":"Arbutus Biopharma Corporation","ticker":"ABUS","cusip":"03879J100","securityClass":"Common Shares, without par value","eventDate":"2026-03-31","reportingPerson":"Two Seas Capital LP","reportingCik":null,"personType":"IA,PN","sharesOwned":18557543,"percentOfClass":9.4,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/abus"},{"accessionNo":"0000921895-26-001101","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001447028","issuerName":"Arbutus Biopharma Corp","ticker":"ABUS","cusip":"03879J100","securityClass":"Common Shares, without par value","eventDate":"2026-04-24","reportingPerson":"David Salanic","reportingCik":null,"personType":"IN,HC","sharesOwned":15794261,"percentOfClass":8,"filedAt":"2026-04-28","canonicalUrl":"https://xoomar.com/markets/stocks/abus"},{"accessionNo":"0000921895-26-001101","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001447028","issuerName":"Arbutus Biopharma Corp","ticker":"ABUS","cusip":"03879J100","securityClass":"Common Shares, without par value","eventDate":"2026-04-24","reportingPerson":"Joseph Kaplan","reportingCik":null,"personType":"IN,HC","sharesOwned":15794261,"percentOfClass":8,"filedAt":"2026-04-28","canonicalUrl":"https://xoomar.com/markets/stocks/abus"},{"accessionNo":"0000921895-26-001101","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001447028","issuerName":"Arbutus Biopharma Corp","ticker":"ABUS","cusip":"03879J100","securityClass":"Common Shares, without par value","eventDate":"2026-04-24","reportingPerson":"Whitefort Capital Management GP, LLC","reportingCik":null,"personType":"OO","sharesOwned":15794261,"percentOfClass":8,"filedAt":"2026-04-28","canonicalUrl":"https://xoomar.com/markets/stocks/abus"},{"accessionNo":"0000921895-26-001101","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001447028","issuerName":"Arbutus Biopharma Corp","ticker":"ABUS","cusip":"03879J100","securityClass":"Common Shares, without par value","eventDate":"2026-04-24","reportingPerson":"Whitefort Capital Management, LP","reportingCik":"0001884931","personType":"IA,PN","sharesOwned":15794261,"percentOfClass":8,"filedAt":"2026-04-28","canonicalUrl":"https://xoomar.com/markets/stocks/abus"},{"accessionNo":"0000921895-26-001101","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001447028","issuerName":"Arbutus Biopharma Corp","ticker":"ABUS","cusip":"03879J100","securityClass":"Common Shares, without par value","eventDate":"2026-04-24","reportingPerson":"Whitefort Capital GP, LLC","reportingCik":null,"personType":"OO","sharesOwned":15794261,"percentOfClass":8,"filedAt":"2026-04-28","canonicalUrl":"https://xoomar.com/markets/stocks/abus"},{"accessionNo":"0000921895-26-001101","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001447028","issuerName":"Arbutus Biopharma Corp","ticker":"ABUS","cusip":"03879J100","securityClass":"Common Shares, without par value","eventDate":"2026-04-24","reportingPerson":"Whitefort Capital Master Fund, LP","reportingCik":"0001704387","personType":"PN","sharesOwned":15794261,"percentOfClass":8,"filedAt":"2026-04-28","canonicalUrl":"https://xoomar.com/markets/stocks/abus"},{"accessionNo":"0000921895-26-000973","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001447028","issuerName":"Arbutus Biopharma Corp","ticker":"ABUS","cusip":"03879J100","securityClass":"Common Shares, without par value","eventDate":"2026-04-10","reportingPerson":"Whitefort Capital Master Fund, LP","reportingCik":"0001704387","personType":"PN","sharesOwned":15794261,"percentOfClass":8.1,"filedAt":"2026-04-13","canonicalUrl":"https://xoomar.com/markets/stocks/abus"},{"accessionNo":"0000921895-26-000973","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001447028","issuerName":"Arbutus Biopharma Corp","ticker":"ABUS","cusip":"03879J100","securityClass":"Common Shares, without par value","eventDate":"2026-04-10","reportingPerson":"Whitefort Capital GP, LLC","reportingCik":null,"personType":"OO","sharesOwned":15794261,"percentOfClass":8.1,"filedAt":"2026-04-13","canonicalUrl":"https://xoomar.com/markets/stocks/abus"},{"accessionNo":"0000921895-26-000973","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001447028","issuerName":"Arbutus Biopharma Corp","ticker":"ABUS","cusip":"03879J100","securityClass":"Common Shares, without par value","eventDate":"2026-04-10","reportingPerson":"Whitefort Capital Management, LP","reportingCik":"0001884931","personType":"IA,PN","sharesOwned":15794261,"percentOfClass":8.1,"filedAt":"2026-04-13","canonicalUrl":"https://xoomar.com/markets/stocks/abus"},{"accessionNo":"0000921895-26-000973","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001447028","issuerName":"Arbutus Biopharma Corp","ticker":"ABUS","cusip":"03879J100","securityClass":"Common Shares, without par value","eventDate":"2026-04-10","reportingPerson":"Whitefort Capital Management GP, LLC","reportingCik":null,"personType":"OO","sharesOwned":15794261,"percentOfClass":8.1,"filedAt":"2026-04-13","canonicalUrl":"https://xoomar.com/markets/stocks/abus"},{"accessionNo":"0000921895-26-000973","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001447028","issuerName":"Arbutus Biopharma Corp","ticker":"ABUS","cusip":"03879J100","securityClass":"Common Shares, without par value","eventDate":"2026-04-10","reportingPerson":"David Salanic","reportingCik":null,"personType":"IN,HC","sharesOwned":15794261,"percentOfClass":8.1,"filedAt":"2026-04-13","canonicalUrl":"https://xoomar.com/markets/stocks/abus"},{"accessionNo":"0000921895-26-000973","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001447028","issuerName":"Arbutus Biopharma Corp","ticker":"ABUS","cusip":"03879J100","securityClass":"Common Shares, without par value","eventDate":"2026-04-10","reportingPerson":"Joseph Kaplan","reportingCik":null,"personType":"IN,HC","sharesOwned":15794261,"percentOfClass":8.1,"filedAt":"2026-04-13","canonicalUrl":"https://xoomar.com/markets/stocks/abus"},{"accessionNo":"0001011438-26-000149","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001447028","issuerName":"Arbutus Biopharma Corp","ticker":"ABUS","cusip":null,"securityClass":"Common Shares, without par value","eventDate":"2025-12-31","reportingPerson":"Two Seas Capital LP","reportingCik":null,"personType":"IA,PN","sharesOwned":12589158,"percentOfClass":6.5,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/abus"},{"accessionNo":"0001011438-26-000149","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001447028","issuerName":"Arbutus Biopharma Corp","ticker":"ABUS","cusip":null,"securityClass":"Common Shares, without par value","eventDate":"2025-12-31","reportingPerson":"Two Seas Capital GP LLC","reportingCik":null,"personType":"OO,HC","sharesOwned":12589158,"percentOfClass":6.5,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/abus"},{"accessionNo":"0001011438-26-000149","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001447028","issuerName":"Arbutus Biopharma Corp","ticker":"ABUS","cusip":null,"securityClass":"Common Shares, without par value","eventDate":"2025-12-31","reportingPerson":"Sina Toussi","reportingCik":null,"personType":"IN,HC","sharesOwned":12589158,"percentOfClass":6.5,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/abus"},{"accessionNo":"0000895421-26-000041","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001447028","issuerName":"Arbutus Biopharma Corp","ticker":"ABUS","cusip":null,"securityClass":"Common Shares","eventDate":"2025-12-31","reportingPerson":"Morgan Stanley","reportingCik":null,"personType":"HC,CO","sharesOwned":25910337,"percentOfClass":13.5,"filedAt":"2026-02-11","canonicalUrl":"https://xoomar.com/markets/stocks/abus"},{"accessionNo":"0000895421-26-000041","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001447028","issuerName":"Arbutus Biopharma Corp","ticker":"ABUS","cusip":null,"securityClass":"Common Shares","eventDate":"2025-12-31","reportingPerson":"Morgan Stanley Investment Management Inc.","reportingCik":null,"personType":"IA,CO","sharesOwned":25647127,"percentOfClass":13.3,"filedAt":"2026-02-11","canonicalUrl":"https://xoomar.com/markets/stocks/abus"}],"updatedAt":"2026-11-03T17:40:47.026Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/abus","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}